Novo Nordisk (NVO.US) pressures FDA to limit semaglutide generics, asks to be added to the list of difficult-to-make drugs

Market IntelWednesday, Oct 23, 2024 10:41 pm ET
1min read

Zhitong Finance APP noticed that Novo Nordisk (NVO.US) has been trying to crack down on compound pharmacies that produce semaglutide, and has told the US Food and Drug Administration that the drug is difficult to produce and could pose safety risks if not produced properly.

The Danish pharmaceutical company has asked the FDA to add semaglutide to its list of drugs that are difficult to prove.

Novo Nordisk's lawyer Covington & Burling wrote in a document: "Semaglutide products are on these lists due to their formulation, delivery mechanism, dosage form, bioavailability, complex compounding process, and physical and chemical and analytical testing."

Semaglutide is the active ingredient in Novo Nordisk's blockbuster weight loss and type 2 diabetes drugs Wegovy and Ozempic.

Novo Nordisk's competitors Eli Lilly and Company produce Tizepatide for weight loss and Mounjaro for diabetes, and both drugs were in short supply for most of 2024 due to their popularity. However, those drugs are no longer in short supply.

If on the FDA's drug shortage list, compound manufacturers can produce drugs that are still under patent protection.

Lilly recently sued three companies that continue to produce and sell compounded Tizepatide.

Comments



Add a public comment...
No comments

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.